Format

Send to

Choose Destination
Pediatr Blood Cancer. 2012 Sep;59(3):576-9. doi: 10.1002/pbc.23383. Epub 2011 Oct 28.

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.

Author information

1
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Knight Cancer Institute, Doernbecher's Childrens Hospital, Oregon Health & Science University, Portland, Oregon, USA.

Abstract

Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.

PMID:
22038978
PMCID:
PMC3291800
DOI:
10.1002/pbc.23383
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center